Tags

Type your tag names separated by a space and hit enter

Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Proc Natl Acad Sci U S A. 2020 04 28; 117(17):9490-9496.PN

Abstract

Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 109/L vs. 0.76 × 109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

Authors+Show Affiliations

China National Biotec Group Company Limited, 100029 Beijing, China. National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.First People's Hospital of Jiangxia District, 430200 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.WuHan Jinyintan Hospital, 430023 Wuhan, China.Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.Clinical Research Center, Department of Gastroenterology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, 200018 Shanghai, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.Wuhan Blood Center, 430030 Wuhan, China.State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.Wuhan Blood Center, 430030 Wuhan, China.Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, National Research Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China. Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China.China National Biotec Group Company Limited, 100029 Beijing, China.China National Biotec Group Company Limited, 100029 Beijing, China.China National Biotec Group Company Limited, 100029 Beijing, China.National Institute for Food and Drug Control of China, 102629 Beijing, China.Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China; zchen@stn.sh.cn zhangx@shsmu.edu.cn yangxiaoming@sinopharm.com.Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, National Research Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China; zchen@stn.sh.cn zhangx@shsmu.edu.cn yangxiaoming@sinopharm.com.China National Biotec Group Company Limited, 100029 Beijing, China; zchen@stn.sh.cn zhangx@shsmu.edu.cn yangxiaoming@sinopharm.com. National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32253318

Citation

Duan, Kai, et al. "Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients." Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 17, 2020, pp. 9490-9496.
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490-9496.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., ... Yang, X. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 117(17), 9490-9496. https://doi.org/10.1073/pnas.2004168117
Duan K, et al. Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients. Proc Natl Acad Sci USA. 2020 04 28;117(17):9490-9496. PubMed PMID: 32253318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of convalescent plasma therapy in severe COVID-19 patients. AU - Duan,Kai, AU - Liu,Bende, AU - Li,Cesheng, AU - Zhang,Huajun, AU - Yu,Ting, AU - Qu,Jieming, AU - Zhou,Min, AU - Chen,Li, AU - Meng,Shengli, AU - Hu,Yong, AU - Peng,Cheng, AU - Yuan,Mingchao, AU - Huang,Jinyan, AU - Wang,Zejun, AU - Yu,Jianhong, AU - Gao,Xiaoxiao, AU - Wang,Dan, AU - Yu,Xiaoqi, AU - Li,Li, AU - Zhang,Jiayou, AU - Wu,Xiao, AU - Li,Bei, AU - Xu,Yanping, AU - Chen,Wei, AU - Peng,Yan, AU - Hu,Yeqin, AU - Lin,Lianzhen, AU - Liu,Xuefei, AU - Huang,Shihe, AU - Zhou,Zhijun, AU - Zhang,Lianghao, AU - Wang,Yue, AU - Zhang,Zhi, AU - Deng,Kun, AU - Xia,Zhiwu, AU - Gong,Qin, AU - Zhang,Wei, AU - Zheng,Xiaobei, AU - Liu,Ying, AU - Yang,Huichuan, AU - Zhou,Dongbo, AU - Yu,Ding, AU - Hou,Jifeng, AU - Shi,Zhengli, AU - Chen,Saijuan, AU - Chen,Zhu, AU - Zhang,Xinxin, AU - Yang,Xiaoming, Y1 - 2020/04/06/ PY - 2020/4/8/pubmed PY - 2020/5/2/medline PY - 2020/4/8/entrez KW - COVID-19 KW - convalescent plasma KW - pilot project KW - treatment outcome SP - 9490 EP - 9496 JF - Proceedings of the National Academy of Sciences of the United States of America JO - Proc. Natl. Acad. Sci. U.S.A. VL - 117 IS - 17 N2 - Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 109/L vs. 0.76 × 109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials. SN - 1091-6490 UR - https://www.unboundmedicine.com/medline/citation/32253318/full_citation L2 - http://www.pnas.org/cgi/pmidlookup?view=long&pmid=32253318 DB - PRIME DP - Unbound Medicine ER -